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Comparison of estimation of volume of 
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D-negative nonisoimmunized mothers
K. Mittal, N. Marwaha, P. Kumar, S.C. Saha, and B. Thakral
In this study we assessed the efficacy of the microcolumn 
gel method in the detection and quantification of the volume 
of fetomaternal hemorrhage (FMH) in comparison with the 
Kleihauer-Betke test (KB) in nonisoimmunized D– mothers. 
We collected blood samples from 80 D– indirect antiglobulin 
test–negative mothers over a span of more than 1 year. FMH 
was determined by KB and microcolumn gel method, and the 
results were compared. FMH was recorded as less than 4 mL by 
KB if no fetal cells were seen after examining 25 fields using 10× 
objective. If fetal cells were seen, slides were examined further to 
quantify FMH. By microcolumn gel method, FMH was reported 
as less than 0.1 percent, 0.1 percent, 0.2 percent, and 0.4 percent 
or greater. None of the patients had FMH greater than 15 mL 
by KB. Sixty-two patients (77.5%) had FMH less than 4 mL by 
KB. In all these cases, FMH was less than or equal to 0.2 percent 
(approximately 4 mL) by microcolumn gel method. The mean 
volume of FMH in the remaining 18 (22.5%) cases by KB was 8.3 
± 1.7 mL. Fifteen (83.3%) of these 18 cases had FMH of at least 
0.4 percent (approximately 8 mL) by gel technology. Three cases 
(16.7%) that differed from KB results had FMH of 0.2 percent 
by microcolumn gel method with a maximal FMH of 6.4 mL by 
KB. FMH was significantly increased in cesarean delivery (mean 
FMH 9.5 ± 0.8 mL, range 7.9–10.4 mL, p = 0.001) and antepartum 
hemorrhage (mean FMH 9.5 ± 0.9 mL, range 7.9–10.4 mL, p < 
0.001). Microcolumn gel method is an effective screening test. 
Technologies like KB and flow cytometry are better options for 
detecting a large volume of FMH. Antepartum hemorrhage and 
cesarean delivery are risk factors for FMH. The 300-µg dose 
appears to be excessive immunoprophylaxis in the majority 
of cases. We need to analyze the relative cost-effectiveness of 
universal administration of 300 µg of Rh immune globulin vs. 
FMH quantitation with subsequent administration of titrated 
doses. Immunohematology 2013;29:105–09.
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Fetomaternal hemorrhage (FMH) is defined as passage of 
fetal cells across the placental interface from the fetal to the 
maternal circulation. Most are small-volume blood transfers 
from fetus to mother with a volume of less than 1 ml.1 
Conversely, large-volume FMH of more than 30 mL occurs in 
only about 3 of 1000 pregnancies.2 Massive FMH may present 
with signs and symptoms such as decreased movement, 
sinusoidal heart rhythms, or fetal anomalies. The detection 
and quantification of FMH in cases of Rh incompatibility 
between the fetus and the mother is crucial in the obstetric 
management of nonisoimmunized D– women. Assessment of 
FMH is an important element in determining the amount of 
Rh immune globulin (RhIG) prophylaxis to be administered to 
nonisoimmunized D– women. The recommended dose of RhIG 
varies among different countries. In India, the recommended 
dose of RhIG prophylaxis for D– women delivering D+ infants 
is 300 μg within 72 hours of delivery without estimation of 
FMH. The dose is sufficient for 15 mL of fetal red cells or 30 
mL of fetal whole blood volume.3
The Kleihauer-Betke test (KB) is among the earliest 
methods developed for FMH quantification and is still widely 
used. The method is sensitive but time-consuming and 
difficult to standardize, and it has poor reproducibility. The 
microcolumn gel method has been a major innovation in the 
field of immunohematology and has recently been introduced 
for the quantification of FMH; this method needs to be 
evaluated for its use in the clinical setting.
Materials and Methods
Eighty D–, indirect antiglobulin test (IAT)–negative 
women who delivered live babies in our institution from 
January 2008 to March 2009 constituted the study population. 
The study was approved by the institutional ethics committee, 
and informed consent was obtained from all patients. Previous 
obstetric history and detailed history of current pregnancy 
were noted. Peripheral venous blood samples were collected, 
two milliliters each in EDTA and plain vials, within 1 hour 
of delivery, before the administration of RhIG prophylaxis. 
Each sample was analyzed by both KB and microcolumn gel 
method, and the results were compared.
KB was performed using a commercial kit (Sigma Aldrich 
Chemie GmbH, Steinheim, Germany) in accordance with the 
manufacturer’s guidelines. Thin blood films were prepared 
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on clean, dry slides. Control samples of cord blood were 
tested with each batch of slides stained. Slides were fixed 
in 80 percent ethanol. The slides were immersed in citrate 
phosphate buffer (pH 3.3) at 37.8°C for 5 minutes. The slides 
were rinsed in tap water and dried. They were then placed 
in citrate phosphate buffer (pH 3.3). The slides were stained 
using acid hematoxylin for 3 minutes, rinsed in tap water, and 
counterstained with eosin for 3 minutes. The controls were 
first examined to ensure that the staining and the preparation 
were satisfactory. A minimum of 25 fields was examined using 
a 10× objective. Fetal cells containing hemoglobin F (HbF) 
were stained densely red and refractile, whereas the adult cells 
containing hemoglobin A (HbA) appeared pale and ghostlike 
as shown in Figure 1. If no fetal cells were seen, the FMH was 
reported as less than 4 mL of fetal red blood cells (RBCs). This 
critical value of 4 mL of RBCs was chosen because even a low 
dose of 100 μg of RhIG as administered in some countries can 
adequately neutralize up to 5 mL of FMH. If fetal cells were 
seen, slides were examined further to estimate the number of 
fetal cells present.
The calculation of FMH is as follows, using the formula 
described by Mollison.4 This assumes that the maternal RBC 
volume is 1800 mL, fetal cells are 22 percent larger than 
maternal cells, and only 92 percent of fetal cells stain darkly. 
The fetal bleed is calculated thus:
Uncorrected volume of bleed = 1800 × fetal cells counted (F)/
adult cells counted (A)
Corrected for fetal volume (1.22) = (1800 × F/A) × 1.22 = J
Corrected for staining efficiency (1.09) = J × 1.09 = fetal bleed
Microcolumn Gel Method
The test is based on consumption of antibody, indirectly 
measured by the use of D+ indicator RBCs. It uses anti-D, so 
that fetal D+ cells with available amounts of D are directly 
measured. The amount of residual anti-D is a function of the 
amount of D+ fetal RBCs present in the maternal sample that 
would have adsorbed the anti-D during incubation. More 
D+ fetal RBCs would be present in the maternal sample in 
case of a larger fetomaternal bleed. This would lead to more 
anti-D adsorbed by the D+ cells and a weaker gel reaction. 
The test was performed using commercial gel tubes (FMH 
kit, Diamed AG, Cressier sur Morat, Switzerland, which has 
since been replaced by Bio-Med ID FMH Screening Test). 
The test is currently not available in the United States. Two 
hundred fifty microliters each of washed packed RBCs of 
postdelivery maternal blood and of all standard cells with 
known percentages of D+ RBCs (≥ 0.4%, 0.2%, 0.1%, and 
< 0.1%) provided in the kit were pipetted into Eppendorf 
tubes. One hundred microliters of ID-Diluent 2 was added to 
each tube. Fifty microliters of ID-FMH anti-D was then added 
to each tube. Tubes were agitated for approximately 5 seconds 
on a vortex mixer and then for 60 minutes on a roller mixer. 
After incubation, tubes were centrifuged for 5 minutes at 800g 
to harvest free anti-D in the supernatant. Fifty microliters of 
ID-FMH DiaCell II (D+ RBCs) was added to all microtubes 
of the ID-Card. Fifty microliters of the RBC-free supernatant 
containing unbound anti-D from each Eppendorf tube was 
then added to the appropriate microtubes of the ID-Card. The 
ID-Card was subsequently incubated and centrifuged. Results 
were read and recorded as follows, and are shown in Figure 
2. The strength of reactivity in the microcolumn gel method 
corresponds to the amount of anti-D left in the supernatant. 
The strength of the cell reaction was compared with the 
reaction strengths of standard cells provided in the kit with 
known percentages of D+ RBCs in a mixture of D– RBCs. 
From this, the percentage of fetal D+ RBCs in the maternal 
sample was estimated and converted to volume of FMH with a 
formula, described later: (1) a compact button of RBCs or few 
agglutinates near the bottom of the microtube, indicating high 
consumption of the antibody equivalent to approximately 0.4 
percent or more of D+ RBCs equivalent to at least 7.2 mL of 
FMH using the formula; (2) partial sedimentation of RBCs with 
agglutinated cells in the lower part of the microtube, indicating 
consumption of the antibody equivalent to approximately 
0.2 percent of D+ RBCs equivalent to 3.6 mL of FMH using 
the formula; (3) agglutination distributed throughout the 
gel, indicating consumption of the antibody equivalent to 
approximately 0.1 percent of D+ RBCs equivalent to 1.8 mL 
Fig. 1 Kleihauer-Betke stain showing pale ghostlike adult red blood 
cells and densely red and refractile fetal cells.
densely red  
fetal red cells
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of FMH using the formula; and (4) agglutinated cells at the 
top of the gel; equivalent to insignificant consumption of the 
antibody, indicative of the presence of less than 0.1 percent D+ 
RBCs equivalent to 1.8 mL or less of FMH using the formula.
Calculation of Fetomaternal Hemorrhage 
FMH was calculated using the formula as per the 
manufacturer’s instructions. Based on a maternal packed 
RBC volume of 1800 mL, the percentage of fetal RBCs can be 
assessed in milliliters using the following formula:
X% × 1800/100 = y mL fetal packed RBCs
The results of the tests using both methods were compared.
Results
The mean age of the patients was 25.3 ± 3.1 years (range 
19–33 years), and the mean period of gestation was 37.9 ± 1.6 
weeks (range 32–42 weeks). The mean gravida was 1.6 ± 0.8 
(range 1–5), and included 50 primigravidae. The ABO blood 
group distribution of the female population showed 29 patients 
were group O (36.3%), 16 were group A (20%), 22 were group 
B (27.5%), and 13 (16.3%) were group AB. Sixty (75%) had 
spontaneous onset of labor, and 20 (25%) patients had cesarean 
delivery. Nine (11.25%) had antepartum hemorrhage, and 5 
(6.3%) patients received antenatal RhIg prophylaxis.
There was no history of maternal trauma or antenatal 
obstetric procedures in any of the patients. There was no fetal 
demise, major congenital anomalies, significant anemia, or 
evidence of hydrops fetalis in any of the fetuses.
The volume of FMH estimation was done using both KB 
and microcolumn gel method on 80 samples and is as shown 
in Table 1.
Table 1. Screening of patient samples for FMH by the KB and the 
microcolumn gel method
Number of cases
FMH (mL) KB Microcolumn gel method
≤ 4 mL 62 (77.5%) 65 (81.3%)*
> 4–15 mL 18 (22.5%) 15 (18.7%)
> 15 mL 0 0
*Of 65 cases, 30 (37.5%) had FMH < 1.8 mL, 23 (28.8%) had FMH 1.8 mL, 
and 12 (15%) had FMH 3.6 mL.
FMH = fetomaternal hemorrhage; KB = Kleihauer-Betke test.
Volume of Fetomaternal Hemorrhage Using 
Kleihauer-Betke Test
Using KB, no fetal RBCs were seen in 62 patients (77.5%) 
after examining 25 fields, and hence the volume of FMH was 
recorded as less than 4 mL of fetal RBCs. In the remaining 18 
patients (22.5%), the volume of FMH ranged between 5.6 mL 
and 10.4 mL, the mean ± 2 SD being 8.3 ± 1.7 mL. In none of 
the patients was the volume of FMH more than 15 mL of fetal 
RBCs, obviating the need of additional RhIG.
Volume of Fetomaternal Hemorrhage Using 
Microcolumn Gel Method
Using the microcolumn gel method, the volume of 
FMH was recorded as calculated using the formula. In 30 
patients (37.5%), the volume of FMH was less than 1.8 mL, 
in 23 patients (28.8%) the volume of FMH was 1.8 mL, and 
the volume of FMH was 3.6 mL in 12 patients (15%). In the 
remaining 15 patients (18.7%), the volume of FMH was at 
least 7.2 mL of fetal RBCs.
Comparison of Volume of Fetomaternal Hemorrhage 
Estimation Using Both Methods
In 62 patients (77.5%) of 80 patients, the volume of FMH 
detected by KB was less than 4 mL, whereas a similar volume 
of FMH of 3.6 mL or less of FMH was detected in 65 (81.3%) 
patients by the microcolumn gel method. In 18 (22.5%) of the 
80 patients, the volume of FMH ranged between 5.6 mL and 
10.4 mL (mean ± 2 SD, 8.3 ± 1.7 mL). With the microcolumn 
gel method, a comparable volume of FMH was seen in 15 
(18.7%) patients. The RBC equivalent antibody consumption 
was at least 7.2 mL of volume. In 3 patients (3.8%), there 
were discrepant results between the microcolumn gel method 
and KB, the former showing 1.8 mL of volume in each case 
as against KB, in which the FMH was 5.6, 5.9, and 6.4 mL 
as shown in Table 2. On the whole, however, both methods 
showed good correlation (Pearson correlation coefficient 
0.892).
Fig. 2 Fetomaternal hemorrhage as seen in microcolumn gel 
method.
≥ 0.4% 0.2% 0.1% < 0.1%
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Table 2. Details of FMH volume in discrepant cases




FMH = fetomaternal hemorrhage; KB = Kleihauer-Betke test.
Cesarean delivery was associated significantly with an 
increased risk of FMH (p = 0.001) as 10 (50%) of 20 cases 
associated with cesarean delivery had a volume of FMH 
of greater than 4 mL. The volume of FMH ranged between 
7.9 mL and 10.4 mL, with the mean ± 2 SD being 9.5 ± 0.8 
mL after cesarean delivery. Seven (77.8%) of 9 patients with 
antepartum hemorrhage had a volume of FMH of greater than 
4 mL (p < 0.001). The volume of FMH in cases associated with 
antepartum hemorrhage ranged between 7.9 mL and 10.4 mL, 
with the mean ± 2 SD being 9.5 ± 0.9 mL (Figures 3 and 4).
Discussion
In the present study, the microcolumn gel method was 
compared with KB for detection of FMH. None of the patients 
had large (> 15 mL) FMH that would require additional RhIg 
administration. Sixty-five patients had low-volume FMH of 
4 mL or less by the microcolumn gel method. KB had FMH 
of less than 4 mL in 62 cases. This was in accordance with 
previous study results of Salama et al.,5 Gómez-Arbonés et 
al.,6 and Dass et al.,7 which showed that the microcolumn gel 
method is a good screening test for estimation of FMH. FMH 
was greater than 10 mL in 3 cases by KB, whereas by the 
microcolumn gel method FMH was at least 7.2 mL. This was 
in accordance with a study conducted by Ben-Haroush et al.,8 
who found four episodes of FMH greater than 10 mL detected 
by flow cytometry and only one episode that was detected 
by gel agglutination method. Hence, for large-volume FMH, 
KB is required for FMH estimation, and the microcolumn gel 
method is not the test of choice. Cohen et al.,9 Li et al.,10 and 
Salim et al.11 were unable to confirm the mode of delivery as a 
risk factor for FMH. However, this conclusion was at variance 
with that of Ness et al.,12 who reported that cesarean delivery 
was a risk factor for FMH. Our results indicate that the risk of 
FMH is significantly increased in cesarean delivery compared 
with vaginal delivery (p < 0.05); thus, the mode of delivery 
is a risk factor for FMH. In our study, none of the patients 
had manual removal of the placenta. Delivery maneuvers, 
episiotomy in labor, and gestational age were also explored 
as possible determinants of FMH but were found not to be 
significant. In a study conducted by Adeniji et al.,13 antepartum 
complications of pregnancy (threatened abortion, pregnancy-
induced hypertension, antepartum hemorrhage) were 
explored as possible determinants of FMH but were found not 
to be significant. In our study, antepartum hemorrhage was 
explored as a possible determinant of FMH and was found to 
be significant.
In India, all D– nonalloimmunized patients who deliver 
a D+ baby by either a normal delivery or a cesarean delivery 
receive a standard postnatal dose of 300 μg of RhIG within 
72 hours of delivery with no requirement for a routine KB,3 
which is sufficient for an FMH volume of approximately 15 
mL of fetal RBCs. For a large majority of patients, this is an 
overdose. We need to analyze the relative cost-effectiveness of 
universal administration of 300 μg of anti-D immunoglobulin 
vs. quantitation of FMH with subsequent administration of 
titrated doses.
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Fig. 4 Distribution of cases according to volume of fetomaternal 
hemorrhage (FMH) with relation to mode of delivery (NVD = normal 














Fig. 3 Distribution of cases according to volume of fetomaternal 
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